Table 2.
Hemodynamic and Electrophysiological Studies
| Control Group (n=10) | DM Group (n=10) | ALLO Group (n=10) | |
|---|---|---|---|
| IACT, ms | 22.10±3.67 | 27.30±2.83a | 23.90±2.6b |
| AVWCL, ms | 159.40±16.44 | 138.90±18.27a | 153.40±14.34b |
| HRAERP, 250 ms | 86.20±12.16 | 90.00±14.36 | 84.00±8.60 |
| HRAERP, 200 ms | 84.80±7.84 | 96.00±16.47 | 86.60±7.49 |
| HLAERP, 250 ms | 84.40±7.65 | 93.40±17.33 | 88.40±11.27 |
| HLAERP, 200 ms | 81.80±7.74 | 93.80±12.27 | 89.40±11.08 |
| LLAERP, 250 ms | 87.20±9.30 | 97.80±13.61 | 90.80±9.94 |
| LLAERP, 200 ms | 89.40±7.43 | 94.20±14.74 | 87.60±11.99 |
| AERPD, ms | 21.00±4.35 | 26.80±5.67a | 22.80±5.98b |
Values are mean±SD. AERPD indicates atrial effective refractory periods dispersion; AVWCL, Wenckebach cycle length of A‐V conduction; DM, diabetes mellitus; HLAERP, high left atrium effective refractory period; HRAERP, high right atrium effective refractory period; IACT, interatrial conduction time; LLAERP, low left atrium effective refractory period.
a
Compared with the control group P<0.05.
b
Compared with the DM group P<0.05.